Harbin Gloria Pharmaceuticals Market Cap ($969.11 Million)
Market Cap & Net Worth: Harbin Gloria Pharmaceuticals (002437)
Harbin Gloria Pharmaceuticals market cap. Harbin Gloria Pharmaceuticals (SHE:002437) has a market capitalization of $969.11 Million (CN¥6.62 Billion) as of November 4, 2026. Listed on the SHE stock exchange, this China-based company holds position #8740 globally and #2021 in its home market, demonstrating a -3.57% decrease in market value over the past year.
Market capitalization, also known as net worth in stock markets, is calculated by multiplying Harbin Gloria Pharmaceuticals's stock price CN¥2.97 by its total outstanding shares 2229868126 (2.23 Billion). Also see 002437 cash generation efficiency for how efficiently the company converts equity into cash flow.
Harbin Gloria Pharmaceuticals Market Cap History (2015–2026)
Harbin Gloria Pharmaceuticals market cap history from 2015 to 2026. Data shows change from $3.22 Billion to $969.11 Million (-10.20% CAGR). Check current stock price of Harbin Gloria Pharmaceuticals for real-time trading data and today's change.
Harbin Gloria Pharmaceuticals Market Cap to Earnings & Revenue Ratios Timeline
This chart shows how Harbin Gloria Pharmaceuticals's valuation ratios have evolved. The Price to Sales (P/S) ratio compares market cap to revenue, while the Price to Earnings (P/E) ratio compares market cap to net income. Lower values may indicate a more undervalued company relative to its financial performance. Explore 002437 net assets growth trend to track how rapidly the company is growing its equity base year over year.
Latest Price to Sales (P/S) Ratio
0.47x
Harbin Gloria Pharmaceuticals's market cap is 0.47 times its annual revenue
Latest Price to Earnings (P/E) Ratio
2.66x
Harbin Gloria Pharmaceuticals's market cap is 2.66 times its annual earnings
What These Ratios Tell Investors:
- Price to Sales (P/S) Ratio: Shows how much investors are paying for each dollar of the company's sales. Lower P/S ratios may indicate undervaluation.
- Price to Earnings (P/E) Ratio: Shows how much investors are paying for each dollar of the company's earnings. This is one of the most common valuation metrics.
- Trends in these ratios over time can indicate changing investor sentiment about the company's future growth prospects.
- Industry comparison provides context for whether the company is valued higher or lower than peers.
| Year | Market Cap (USD) | Revenue (USD) | Net Income (USD) | P/S Ratio | P/E Ratio |
|---|---|---|---|---|---|
| 2016 | $2.66 Billion | $2.98 Billion | $716.65 Million | 0.89x | 3.72x |
| 2017 | $2.24 Billion | $3.04 Billion | $309.68 Million | 0.73x | 7.22x |
| 2018 | $910.96 Million | $5.48 Billion | $125.89 Million | 0.17x | 7.24x |
| 2019 | $988.69 Million | $5.05 Billion | -$2.66 Billion | 0.20x | N/A |
| 2020 | $1.04 Billion | $3.05 Billion | $400.05 Million | 0.34x | 2.61x |
| 2021 | $949.53 Million | $3.15 Billion | $45.04 Million | 0.30x | 21.08x |
| 2022 | $828.80 Million | $3.11 Billion | -$291.33 Million | 0.27x | N/A |
| 2023 | $819.01 Million | $2.63 Billion | $120.33 Million | 0.31x | 6.81x |
| 2024 | $812.49 Million | $2.44 Billion | $232.76 Million | 0.33x | 3.49x |
| 2025 | $1.00 Billion | $2.14 Billion | $376.91 Million | 0.47x | 2.66x |
Competitor Companies of 002437 by Market Capitalization
Companies near Harbin Gloria Pharmaceuticals in the global market cap rankings as of November 4, 2026. Also see 002437 total assets for a full breakdown of the balance sheet.
Key companies related to Harbin Gloria Pharmaceuticals by market ranking:
- Takeda Pharmaceutical Co Ltd ADR (NYSE:TAK): Ranked #516 globally with a market cap of $52.60 Billion USD.
- GALDERMA GROUP AG (NYSE:GALDY): Ranked #536 globally with a market cap of $50.42 Billion USD.
- Jiangsu Hengrui Medicine Co Ltd (SHG:600276): Ranked #591 globally with a market cap of $45.45 Billion USD ( CN¥310.59 Billion CNY).
- Takeda Pharmaceutical Company Limited (F:TKDA): Ranked #618 globally with a market cap of $43.60 Billion USD ( €37.29 Billion EUR).
| Rank | Company | Symbol | Market Cap | Price |
|---|---|---|---|---|
| #516 | Takeda Pharmaceutical Co Ltd ADR | NYSE:TAK | $52.60 Billion | $16.65 |
| #536 | GALDERMA GROUP AG | NYSE:GALDY | $50.42 Billion | $46.55 |
| #591 | Jiangsu Hengrui Medicine Co Ltd | SHG:600276 | $45.45 Billion | CN¥48.69 |
| #618 | Takeda Pharmaceutical Company Limited | F:TKDA | $43.60 Billion | €18.50 |
Market Capitalization of Harbin Gloria Pharmaceuticals (2015–2026)
Market capitalization of Harbin Gloria Pharmaceuticals from 2015 to today. Between 2015 and today, Harbin Gloria Pharmaceuticals's market cap moved from $3.22 Billion to $ 969.11 Million, with a yearly change of -10.20%.
| Year | Market Cap | Change (%) |
|---|---|---|
| 2026 | CN¥969.11 Million | -3.26% |
| 2025 | CN¥1.00 Billion | +23.29% |
| 2024 | CN¥812.49 Million | -0.80% |
| 2023 | CN¥819.01 Million | -1.18% |
| 2022 | CN¥828.80 Million | -12.71% |
| 2021 | CN¥949.53 Million | -9.06% |
| 2020 | CN¥1.04 Billion | +5.61% |
| 2019 | CN¥988.69 Million | +8.53% |
| 2018 | CN¥910.96 Million | -59.25% |
| 2017 | CN¥2.24 Billion | -16.06% |
| 2016 | CN¥2.66 Billion | -17.27% |
| 2015 | CN¥3.22 Billion | -- |
End of Day Market Cap According to Different Sources
On Nov 3rd, 2026 the market cap of Harbin Gloria Pharmaceuticals was reported to be:
| Source | Market Cap |
|---|---|
| Yahoo Finance | $969.11 Million USD |
| MoneyControl | $969.11 Million USD |
| MarketWatch | $969.11 Million USD |
| marketcap.company | $969.11 Million USD |
| Reuters | $969.11 Million USD |
Market cap values may vary slightly between sources due to differences in calculation methods, timing, and data refresh rates.
About Harbin Gloria Pharmaceuticals
HARBIN GLORIA PHARMACEUTICALS Co., LTD engages in the research, development, production, and sale of pharmaceutical products in the People's Republic of China. Its products include cardiovascular and cerebrovascular, musculoskeletal, vitamins, electrolyte, diabetes-lowering, analgesics, digestive system and metabolism, anti-infective, and anti-tumor drugs. Harbin Gloria Pharmaceuticals Co., Ltd w… Read more